S. 5242 · 119th Congress · Health

Prescription Information Modernization Act of 2026

In committee366 words Introduced Aug 4, 2026 · Latest action Aug 4, 2026

How far it has goneStage 2 of 6
  1. IntroducedAug 4, 2026 Done
  2. CommitteeReferred to Health, Education, Labor, and Pensions Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 366 words

S. 5242 · Introduced in Senate · Aug 4, 2026

SECTION 1. SHORT TITLE.

This Act may be cited as the Prescription Information Modernization Act of 2026 .

SEC. 2. DIGITAL COMMUNICATION OF FDA-APPROVED PRESCRIBING INFORMATION FOR DRUGS (INCLUDING BIOLOGICAL PRODUCTS).

(a) In general. Section 502(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352(f) ) is amended by adding at the end the following: Required prescribing information for drugs subject to section 503(b)(1) may be made available solely by electronic means, provided that the labeling complies with all applicable requirements of law, that the manufacturer affords prescribers and dispensers the opportunity to elect to also continue to receive all such information in paper form or to request paper labeling on an as-needed basis, and, after such request, that the manufacturer promptly provides the requested information without additional cost. .

(b) Rulemaking. (1) In general Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue final regulations to— (A) implement the amendment made by subsection (a); and (B) provide instructions on how health care professionals can receive paper copies of prescribing information directly from the manufacturer or distributor if desired. (2) Economic impacts The Secretary of Health and Human Services shall design the regulations required by paragraph (1) so as to minimize the adverse economic impacts of such regulations on prescribers and dispensers.

(c) Public workshop. Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall hold a public workshop with relevant stakeholders to discuss how to continue to optimize the format, accessibility, and usability of prescribing information.

(d) Effective date. The amendment made by subsection (a) shall apply with respect to drugs introduced or delivered for introduction into interstate commerce on or after the sooner of— (1) the date that is 2 years after the date of the enactment of this Act; or (2) the effective date of the final regulations promulgated to implement such amendment.

(e) Definition. In this section, the term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

No lobbying filing on file names S. 5242.

Organizations that named S. 5242 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Aug 4, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Aug 4, 2026Introduced in Senate